Sigyn Therapeutics (SIGY) Notes Payables (2016 - 2025)

Sigyn Therapeutics has disclosed Notes Payables across 10 years of filings, most recently posting $2.5 million for Q3 2025.

• In Q3 2025, Notes Payables rose 40.13% year-over-year to $2.5 million; the TTM figure through Sep 2025 stood at $2.5 million (up 40.13% YoY), while the FY2024 annual figure was $1.9 million, changed 0.0% from the prior year.
• Notes Payables came in at $2.5 million for Q3 2025 at Sigyn Therapeutics, up from $2.3 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $2.9 million in Q3 2023 to a low of $578254.0 in Q1 2021.
• Average Notes Payables over 5 years is $1.7 million, with a median of $1.8 million recorded in 2024.
• Year-over-year, Notes Payables tumbled 67.81% in 2021 and soared 250.55% in 2023.
• Over 5 years, Notes Payables stood at $647202.0 in 2021, then surged by 152.88% to $1.6 million in 2022, then increased by 15.59% to $1.9 million in 2023, then changed by 0.0% to $1.9 million in 2024, then surged by 32.66% to $2.5 million in 2025.
• Per Business Quant data, the three most recent Notes Payables figures were $2.5 million in Q3 2025, $2.3 million in Q2 2025, and $2.2 million in Q1 2025.